Zacks.com on MSN2d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...
Denali Therapeutics recently disclosed the outcomes of its HEALEY trial, which evaluated DNL343, an agonist of eIF2B intended for the treatment of amyotrophic lateral sclerosis (ALS). The trial failed ...
The revision followed the announcement that Denali's DNL343, an eIF2B inhibitor, did not achieve the primary or key secondary endpoints in the phase 2/3 HEALEY trial for amyotrophic lateral sclerosis ...
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback